HPV Logo

MENU

Milestones

Milestones

The following is a list of milestone documents, compiled by the National HPV Vaccination Roundtable, which chronicle notable events in U.S.-based HPV vaccine history, from 2006 to present.

2018

President's Cancer Panel issues a report: HPV Vaccination for Cancer Prevention: Progress, Opportunities, and a Renewed Call to Action

2018

FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old

2016

Cancer Moonshot Blue Ribbon Panel Report highlights cancer prevention potential of HPV vaccination

2016

ACIP updates recommendations on use of a 2-dose schedule for HPV vaccination

2016

NCI-designated Cancer Centers issue consensus statement on HPV vaccination

2015

ACIP issues updated recommendations on use of 9-valent HPV vaccine

2014

FDA approves nine valent vaccination (9vHPV/Gardasil 9)

Gardasil 9 package insert: Link

2014

National HPV Vaccination Roundtable established by the American Cancer Society and the Centers for Disease Control and Prevention

2014

ACIP issues new recommendations for HPV vaccination

2014

President’s Cancer Panel issues 2012-2013 Report: Accelerating HPV Vaccine Uptake: Urgency for Action to Prevent Cancer

2010

ACIP issues guidance on quadrivalent vaccine (HPV4/Gardasil) for use in males

2010

ACIP issues updated HPV vaccination recommendations for HPV2 and HPV4 for females

2009

FDA licenses quadrivalent HPV vaccine (HPV4/Gardasil) for use in males aged 9 through 26 years for prevention of genital warts on October 16, 2009

2009

FDA licenses bivalent HPV vaccine (HPV2/Cervarix) for females on October 16, 2009

2007

Advisory Committee on Immunization Practices (ACIP) issues recommendations on quadrivalent HPV vaccine

2006

U.S. Food and Drug Administration (FDA) approves quadrivalent (HPV4/Gardasil) human papillomavirus vaccine for females on June 8, 2006

Twitter Feed